hapabapa/iStock Editorial by way of Getty Pictures
Novo Nordisk (NVO) introduced Saturday that its FDA-approved weight reduction remedy Wegovy, also called semaglutide, led to cardiovascular advantages no matter age, gender, ethnicity, and weight problems stage in a Section 3 trial.
In August, the Danish drugmaker mentioned that the trial referred to as SELECT achieved its main objective because the GLP-1 receptor agonist at 2.4 mg led to a 20% threat discount from main antagonistic cardiovascular occasions (MACE) reminiscent of stroke with a statistically important impact.
Saying its detailed outcomes at a medical occasion organized by the American Coronary heart Affiliation (AHA), the corporate mentioned that the danger discount in MACE was seen no matter sufferers’ age, gender, ethnicity, and beginning physique mass index (BMI).
The advantages had been seen quickly after beginning the remedy, which, in keeping with the corporate, signifies that there won’t be a connection between the drug’s weight reduction results and its cardiovascular advantages.
The worldwide examine enrolled greater than 17K overweight or chubby adults with heart problems and no prior historical past of diabetes.
Different highlights of the trial point out that semaglutide, in comparison with placebo, led to a statistically important 28% threat discount in coronary heart assaults.
Nonetheless, findings a couple of 7% threat discount in non-fatal strokes and a 15% threat discount in cardiovascular demise weren’t statistically important.
Novo (NVO) mentioned that the semaglutide 2.4 mg dose in SELECT appeared protected and demonstrated a tolerability profile in keeping with prior research.
The corporate expects the U.S. and EU to determine subsequent yr on its bid to increase semaglutide labeling to incorporate a sign for cardiovascular threat discount.
